Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | GLI1 | P08151 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537702 | 0.88 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL7536202 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL1680032 | 0.88 | GRIK1 (0.37) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL2201568 | 0.86 | NOS2 (0.33) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL285831 | 0.85 | NOS2 (0.37) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL756555 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL11858950 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL1537227 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL51271 | 0.84 | NOS2 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL10940484 | 0.83 | CTSC (0.45) | DPP7DPP4DPP8DPP9ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099452-A1 | DIALYSIS FLUID COMPRISING KETONE BODIES FOR THE TREATMENT OF CANCER | GAMBRO LUNDIA AB (SE) | 2023-06-08 | — | — | WO | claimed |
| WO-2023099436-A1 | NEW DIALYSIS FLUID | GAMBRO LUNDIA AB (SE) | 2023-06-08 | — | — | WO | claimed |
| CN-105327081-A | Traditional Chinese medicine composition for preventing and curing emphysema and preparation method | LI TAO | 2016-02-17 | — | — | CN | disclosed |
| CN-105288193-A | Yin nourishing and heat clearing preparation for treating pulmonary heart diseases, and preparation method thereof | LI TAO | 2016-02-03 | — | — | CN | disclosed |
| CN-105233033-A | Preparation for treating nervous tinnitus and preparation method of preparation | LI YOUHUA | 2016-01-13 | — | — | CN | disclosed |
| US-20130338069-A1 | Preparation of a Therapeutic Composition | OHR PHARMACEUTICAL INC. (US) | 2013-12-19 | — | — | US | disclosed |
| CN-102822413-A | Process of treatment of fibers and/or textile materials | LIPOTEC SA | 2012-12-12 | — | — | CN | disclosed |
| US-20120271032-A1 | Preparation of a Therapeutic Composition | OHR PHARMACEUTICAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8084239-B2 | Preparation of a therapeutic composition | Ohr Pharmaceuticals, Inc (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100080820-A1 | Preparation of a Therapeutic Composition | BBM HOLDINGS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7524661-B2 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20060177514-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2006-08-10 | — | — | US | disclosed |
| US-7074767-B2 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6921542-B2 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20030158107-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2003-08-21 | — | — | US | disclosed |
| US-20030134782-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2003-07-17 | — | — | US | disclosed |
| US-6528098-B2 | Viricides | ADVANCED VIRAL RESEARCH CORP. | 2003-03-04 | — | — | US | disclosed |
| US-20020004579-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158107-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | NOS2 3235/4885NOS3 3243/4885NOS1 3649/4885 |
| US-20020004579-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | NOS2 3235/4885NOS3 3243/4885NOS1 3649/4885 |
| US-20030134782-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | NOS2 3235/4885NOS3 3243/4885NOS1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.